Asacolon 1600 mg modified-release tablets

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

Mesalazine

Available from:

Tillotts Pharma GmbH

ATC code:

A07EC; A07EC02

INN (International Name):

Mesalazine

Dosage:

1600 milligram(s)

Pharmaceutical form:

Modified-release tablet

Prescription type:

Product subject to prescription which may be renewed (B)

Therapeutic area:

Aminosalicylic acid and similar agents; mesalazine

Authorization status:

Marketed

Authorization date:

2018-02-23

Patient Information leaflet

1
PACKAGE LEAFLET: INFORMATION FOR THE USER
ASACOLON 1600 MG MODIFIED-RELEASE TABLETS
mesalazine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if
their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects
not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Asacolon is and what it is used for
2.
What you need to know before you use Asacolon
3.
How to use Asacolon
4.
Possible side effects
5.
How to store Asacolon
6.
Contents of the pack and other information
1.
WHAT ASACOLON IS AND WHAT IT IS USED FOR
Asacolon contains the active substance mesalazine. It is an
anti-inflammatory medicine used for the
treatment of ulcerative colitis. Ulcerative colitis is a disease in
which the lining of the large intestine (colon)
or the back passage (rectum) becomes inflamed (red and swollen). This
may lead to frequent and bloody
stools, often with abdominal cramps.
Asacolon treats and prevents inflammation throughout the entire colon
and rectum (mild to moderate acute
ulcerative colitis and for the prevention of relapse).
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE ASACOLON
DO NOT USE ASACOLON:
-
if you are allergic to mesalazine or any of the other ingredients of
this medicine (listed in section 6).
-
if you are allergic to salicylates (e.g. acetylsalicylic acid)
-
if you have severe liver problems
-
if you have severe kidney problems
WARNINGS AND PRECAUTIONS
Talk to your doctor or pharmacist before using Asacolon if you have
any medical conditions or illnesses,
particularly if you have:
-
any lung disease problems, e.g. asthma.
-
impaired function of kidneys, liver or lungs, especially if you are
elderly.
-
suffered an allerg

Summary of Product characteristics

Health Products Regulatory Authority
04 July 2023
CRN00DPGG
Page 1 of 8
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Asacolon 1600 mg modified-release tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each modified-release tablet contains: 1600 mg mesalazine.
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Modified-release tablet.
Film-coated, red/brown oblong tablets dimension of 23 x 11 x 9 mm.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
_Ulcerative colitis._
For the treatment of mild to moderate acute disease. For the
maintenance of remission.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Adults, including the elderly (>65 years)
The dose should be adjusted according to the severity of the disease
and tolerance.
_Acute disease_: In the event of exacerbation, the dose can be
increased to 4800 mg daily, once daily or in 2-3 divided doses.
Once clinical remission is achieved, the dose should gradually be
decreased to maintenance dose.
Continued therapy should be carefully considered in subjects not
responding by week 8.
_Maintenance treatment_: 1600 mg once daily.
_ _
Other oral mesalazine formulations are available if an alternative
dose for maintenance treatment is considered more
appropriate.
_ _
Elderly population
_ _
No studies have been carried out in older people.
Paediatric population
The safety and efficacy of Asacolon in children and adolescents aged
younger than 18 years of age have not been established.
Method of administration: oral.
The tablets must be swallowed whole with a glass of water. They must
not be chewed, crushed or broken before swallowing.
The tablets can be taken with or without food.If one or more doses
have been missed, the next dose is to be taken as usual.
Health Products Regulatory Authority
04 July 2023
CRN00DPGG
Page 2 of 8
4.3 CONTRAINDICATIONS

Hypersensitivity to salicylates (including mesalazine) or any of the
excipients listed in section 6.1.

Severe liver impairment.

Severe renal impairment (GFR < 30 mL/mi